Document is current
Any future updates will be listed below
-
Authors
Guillen-Burgos, Hernán F.
Gálvez-Flórez, Juan F.
Moreno-López, Sergio
Solano, María C.
Kwan, Angela T. H.
Santamaria-Garcia, Hernando
Gómez-Restrepo, Carlos
McIntyre, Roger S.
-
Funding
Funding for this research was provided by:
Universidad Simon Bolivar
Universidad El Bosque
Center for Clinical and Translational Research, Bogota, Colombia
- License Information
-
More Information
Article History
Received: 31 May 2024
Accepted: 14 April 2025
First Online: 7 May 2025
Declarations
:
: All participants provided informed consent to participate in this research, including consent for future data publication. The study adhered to the principles outlined in the Declaration of Helsinki, CIOMS guidelines, and national regulations, including Act 8430/1993 and Act 2378/2008, in accordance with Good Clinical Practice in Human Research Studies. Ethics approval was granted by the Ethics Committee of Universidad Simón Bolívar (study code: PRO-CIE-USB-CE-0385-00).
: H.G.B.: Received research grant support from the Ministry of Science, Technology, and Innovation (MinCiencias) in Colombia and UKRI in the United Kingdom; also received speaker fees from Roche, Pfizer, Abbott, GSK, and Synergy R&D. S.M., M.C.S., A.T.H.K., H.S.M., and C.G.R.: Declare no conflicts of interest. J.F.G.F.: Employed part-time by Universidad El Bosque, Center for Clinical and Translational Research, Bogotá, Colombia. R.S.M.: Received research grant support from CIHR/GACD/National Natural Science Foundation of China and the Milken Institute; also received speaker and consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, and Atai Life Sciences. R.S.M. is also the CEO of Braxia Scientific Corp.
